Lead Product(s): Cannabidiol
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Health Canada
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 15, 2020
Dalton receives the license amendment from Health Canada under Cannabis regulations enabling transfer of finished cGMP cannabis products to licensed dealers.